Revision per component name

Cemented primary TKA – overall revision
Uncemented primary TKA – overall revision
Cemented primary TKA – major revision
Uncemented primary TKA – major revision
Bone cement
TKA by ODEP 5A or higher
TKA by type of femur

Knee » Survival TKA » Revision per component name » Cemented primary TKA – overall revision

TABLE Cumulative revision percentages of cemented primary total knee arthroplasties by prosthesis component combination of patients who underwent a TKA for osteoarthritis in the Netherlands in 2007-2022 (n=287,967)

					Type of revision (n)						Cumulative revision percentage Kaplan Meier (95% CI)
Femur component	Tibia component	Total primary TKAs (n)	Median (IQR) age (yr)	Total RAs (n)	Total knee (complete revision)	Patella addition	Only femur component	Only tibia component	Only insert/ patella	Missing/ unknown	1yr	3yr	5yr	7yr	10yr	14yr
All cemented TKAs for osteoarthritis		287,967	69 (63-76)	12,339	4,322	2,332	501	1,079	3,799	306	0.9 (0.9-1.0)	3.2 (3.1-3.3)	4.2 (4.1-4.3)	4.8 (4.8-4.9)	5.7 (5.6-5.8)	6.8 (6.6-7.0)
Genesis II	Genesis II	63,915	69 (63-75)	3,101	739	679	235	215	1.160	73	1.2 (1.1-1.3)	3.9 (3.7-4.0)	5.0 (4.8-5.1)	5.6 (5.3-5.8)	6.3 (6.1-6.5)	7.3 (6.9-7.7)
NexGen	NexGen	60,333	69 (63-75)	2,559	1,060	277	74	308	773	67	0.9 (0.8-0.9)	2.8 (2.6-2.9)	3.8 (3.6-3.9)	4.7 (4.5-4.9)	5.9 (5.6-6.1)	7.2 (6.8-7.6)
Vanguard Complete Knee	Vanguard Complete Knee	48,103	69 (62-75)	1,793	622	332	45	134	617	43	0.9 (0.8-1.0)	3.0 (2.8-3.1)	3.7 (3.5-3.9)	4.3 (4.1-4.5)	4.9 (4.7-5.2)	6.0 (5.5-6.5)
PFC / SIGMA	PFC / SIGMA	31,886	70 (63-76)	1,221	376	276	31	89	418	31	0.9 (0.8-1.0)	3.0 (2.8-3.2)	3.7 (3.5-4.0)	4.1 (3.8-4.3)	4.6 (4.4-4.9)	5.1 (4.7-5.4)
LCS	LCS	17,251	70 (63-76)	789	413	84	34	145	102	11	0.6 (0.5-0.7)	3.1 (2.9-3.4)	4.2 (3.9-4.5)	4.7 (4.4-5.1)	5.3 (4.9-5.7)	5.8 (5.4-6.3)
Triathlon	Triathlon	10,507	70 (64-76)	365	102	60	16	34	148	5	1.3 (1.1-1.5)	3.5 (3.1-3.9)	4.4 (3.9-4.8)	4.9 (4.4-5.5)	5.4 (4.8-6.1)	n.a.
Persona	Persona	5,811	69 (62-74)	79	14	10	0	7	47	1	0.8 (0.6-1.1)	3.1 (2.1-4.0)	4.9 (3.1-6.6)	5.3 (3.4-7.2)	n.a.	n.a.
Attune	Attune	5,546	70 (63-75)	73	17	16	3	10	26	1	0.6 (0.3-0.8)	2.3 (1.7-2.9)	2.9 (2.1-3.6)	3.1 (2.2-3.9)	n.a.	n.a.
AGC V2	AGC V2	4,420*	71 (65-77)	185	106	58	1	2	12	6	0.3 (0.1-0.5)	2.0 (1.6-2.4)	2.6 (2.1-3.1)	3.2 (2.7-3.7)	3.9 (3.3-4.5)	5.1 (4.3-5.8)
balanSys	balanSys	4,087	69 (62-76)	191	64	72	4	11	36	4	0.9 (0.6-1.1)	3.8 (3.1-4.4)	4.9 (4.2-5.7)	5.8 (4.9-6.7)	6.8 (5.7-7.9)	8.4 (6.7-10.1)
TC Plus	TC Plus	3,729	70 (63-76)	119	58	32	2	5	17	5	0.7 (0.4-0.9)	2.3 (1.8-2.8)	3.0 (2.4-3.6)	3.4 (2.8-4.0)	4.1 (3.3-4.9)	4.6 (3.6-5.6)
Optetrak	Optetrak	3,073*	70 (62-76)	385	231	90	3	33	21	7	1.1 (0.7-1.4)	5.3 (4.5-6.1)	7.1 (6.2-8.0)	9.1 (8.1-10.2)	12.4 (11.2-13.7)	17.5 (15.4-19.6)
ACS	ACS	2,684	67 (60-73)	141	35	22	9	12	55	8	0.7 (0.4-1.0)	3.8 (3.0-4.5)	4.8 (3.9-5.6)	5.1 (4.3-6.0)	5.5 (4.6-6.4)	n.a.
Scorpio NRG	Scorpio	2,631*	70 (63-76)	140	49	47	10	4	29	1	0.8 (0.5-1.2)	3.2 (2.5-3.8)	4.5 (3.7-5.3)	5.1 (4.2-6.0)	5.7 (4.7-6.6)	n.a.
Scorpio	Scorpio	2,240*	71 (63-76)	117	62	22	3	6	20	4	0.3 (0.1-0.5)	2.4 (1.7-3.0)	3.2 (2.5-3.9)	3.7 (2.9-4.5)	4.7 (3.8-5.6)	6.0 (4.9-7.1)
MRK	MRK	1,610	70 (63-76)	31	14	8	0	0	8	1	0.1 (0.0-0.3)	1.4 (0.7-2.0)	2.7 (1.6-3.8)	3.7 (2.3-5.1)	n.a.	n.a.
Journey BCS	Journey BCS	1,566	69 (62-75)	138	19	64	1	3	49	2	1.0 (0.5-1.5)	5.5 (4.3-6.8)	6.8 (5.4-8.2)	8.7 (7-10.3)	10.9 (8.9-12.8)	16.9 (13.4-20.4)
NexGen GSF	NexGen	1,252	68 (61-74)	33	19	5	0	1	7	1	0.5 (0.1-0.9)	1.5 (0.8-2.2)	2.5 (1.6-3.4)	2.7 (1.8-3.7)	3.2 (2.1-4.4)	n.a.
PFC / SIGMA	LCS	1,212*	66 (58-75)	55	28	11	3	1	10	2	0.3 (0.0-0.7)	1.9 (1.1-2.7)	2.9 (1.9-3.8)	3.9 (2.7-5.0)	4.6 (3.3-5.8)	5.8 (4.1-7.4)
Journey II BCS	Journey BCS	1,137	65 (60-72)	72	15	28	0	0	27	2	0.4 (0.0-0.7)	4.5 (3.2-5.8)	6.0 (4.5-7.4)	7.0 (5.3-8.7)	n.a.	n.a.
Innex	Innex	1,126*	70 (62-77)	39	14	10	0	4	11	0	1.0 (0.4-1.6)	2.2 (1.3-3.0)	2.8 (1.8-3.8)	3.2 (2.1-4.2)	3.4 (2.3-4.5)	3.7 (2.6-4.9)
Evolution MP	Evolution MP	946	69 (63-74)	24	6	9	0	0	8	1	0.7 (0.1-1.2)	2.1 (1.1-3.1)	3.5 (2.0-5.0)	n.a.	n.a.	n.a.
Profix	Profix	772*	68 (61-76)	60	41	7	2	2	7	1	0.5 (0.0-1.0)	3.7 (2.3-5.0)	5.6 (3.9-7.2)	6.6 (4.8-8.3)	7.7 (5.8-9.6)	8.5 (6.4-10.6)
Genesis II	Profix / Genesis MB baseplate	622*	67 (60-75)	66	27	30	0	1	7	1	1.0 (0.2-1.8)	6.9 (4.9-8.9)	9.0 (6.7-11.3)	10.3 (7.8-12.7)	11.2 (8.7-13.8)	11.2 (8.7-13.8)
Rotaglide	Rotaglide	428*	72 (65-78)	43	29	3	2	0	9	0	0.9 (0.0-1.9)	4.5 (2.5-6.5)	5.9 (3.7-8.2)	7.2 (4.7-9.6)	10.3 (7.3-13.3)	12.8 (7.8-17.7)
Advance MP	Advance	314*	71 (65-78)	33	7	7	1	5	10	3	1.9 (0.4-3.4)	7.7 (4.7-10.6)	9.0 (5.8-12.1)	9.3 (6.1-12.5)	9.7 (6.4-12.9)	n.a.
Maxim	Vanguard Complete Knee	272*	70 (63-77)	14	3	3	1	2	5	0	1.5 (0.0-2.9)	2.9 (0.9-4.9)	3.3 (1.2-5.4)	4.1 (1.7-6.4)	4.8 (2.3-7.4)	5.2 (2.5-7.8)

* Denotes prosthesis combinations with no reported use in primary TKAs in 2022.
Please note: n.a. if <50 cases were at risk; TKA: total knee arthroplasty; RA: revision arthroplasty; CI: confidence interval; IQR: interquartile range.

Only combinations with over 250 procedures have been listed.
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure of the prosthesis may have influenced the cumulative revision percentages.

Knee » Survival TKA » Revision per component name » Uncemented primary TKA – overall revision

TABLE Cumulative revision percentages of uncemented primary total knee arthroplasties by prosthesis component combination of patients who underwent a TKA for osteoarthritis in the Netherlands in 2007-2022 (n=14,982)

					Type of revision (n)						Cumulative revision percentage Kaplan Meier (95% CI)
Femur component	Tibia component	Total primary TKAs (n)	Median (IQR) age (yr)	Total RAs (n)	Total knee (complete revision)	Patella addition	Only femur component	Only tibia component	Only insert/ patella	Missing/ unknown	1yr	3yr	5yr	7yr	10yr	14yr
All uncemented TKAs for osteoarthritis		14,982	69 (62-75)	673	242	99	13	121	190	18	1.0 (0.8-1.1)	3.6 (3.3-3.9)	4.5 (4.1-4.8)	5.0 (4.6-5.4)	5.6 (5.2-6.1)	6.4 (5.8-7.0)
LCS	LCS	9,032	69 (63-76)	403	115	45	9	94	120	4	0.9 (0.7-1.1)	3.5 (3.1-3.9)	4.2 (3.7-4.6)	4.5 (4.0-5.0)	5.0 (4.5-5.5)	5.4 (4.8-6.0)
Triathlon	Triathlon	2,293	68 (62-74)	43	14	6	0	3	16	0	0.5 (0.2-0.9)	1.7 (1.0-2.3)	2.4 (1.5-3.3)	2.9 (1.9-3.9)	3.6 (2.2-4.9)	n.a.
ACS	ACS	702	69 (61-75)	32	11	7	1	4	8	0	2.0 (0.9-3.1)	4.6 (2.9-6.3)	5.1 (3.3-7.0)	5.4 (3.5-7.3)	n.a.	n.a.
Attune	Attune	467	67 (61-73)	12	3	2	0	0	7	0	1.2 (0.1-2.3)	6.1 (2.4-9.8)	n.a.	n.a.	n.a.	n.a.
Duracon	Duracon	296*	69 (61-77)	10	4	1	0	0	4	0	0.4 (0.0-1.0)	0.7 (0.0-1.7)	1.4 (0.0-2.8)	1.4 (0.0-2.8)	3.1 (1.0-5.1)	3.5 (1.2-5.7)
Rotaglide	Rotaglide	271*	69 (61-77)	63	40	11	1	1	7	1	1.5 (0.0-3.0)	10.3 (6.6-14.0)	16.3 (11.8-20.8)	19.8 (14.8-24.7)	22.7 (17.4-28.0)	n.a.
NexGen	NexGen	241	69 (63-77)	18	8	1	1	3	5	0	1.7 (0.1-3.4)	5.3 (2.4-8.3)	7.1 (3.6-10.5)	8.0 (4.1-11.9)	9.0 (4.7-13.4)	n.a.
ACS LD	ACS LD	249*	70 (61-76)	18	6	3	0	2	3	0	1.3 (0.0-2.8)	5.7 (2.7-8.7)	6.3 (3.1-9.5)	n.a.	n.a.	n.a.
Genesis II	Genesis II	234	69 (62-75)	11	5	2	0	1	1	1	0.9 (0.0-2.2)	4.9 (1.9-7.9)	4.9 (1.9-7.9)	4.9 (1.9-7.9)	4.9 (1.9-7.9)	n.a.
Vanguard Complete Knee	Vanguard Complete Knee	168	67 (61-74)	15	7	2	0	4	1	0	2.5 (0.1-4.9)	5.7 (2.1-9.4)	5.7 (2.1-9.4)	7.6 (3.2-12)	10.1 (4.6-15.6)	n.a.
Triathlon	Triathlon Tritanium	112	69 (64-72)	0	0	0	0	0	0	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

Only combinations with over 100 procedures have been listed.
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure of the prosthesis may have influenced the cumulative revision percentages.

Knee » Survival TKA » Revision per component name » Cemented primary TKA – major revision

TABLE Cumulative major revision percentages of cemented primary total knee arthroplasties by prosthesis component combination of patients who underwent a TKA for osteoarthritis in the Netherlands in 2007-2022 (n=287,967)

					Cumulative major revision percentage Kaplan Meier (95% CI)
Femur component	Tibia component	Total primary TKAs (n)	Median (IQR) age (yr)	Major revision¹ arthroplasties (n)	1yr	3yr	5yr	7yr	10yr	14yr
All cemented TKAs for osteoarthritis		287,967	69 (63-76)	6,576	0.3 (0.3-0.4)	1.5 (1.5-1.6)	2.1 (2.1-2.2)	2.6 (2.5-2.7)	3.2 (3.1-3.3)	3.9 (3.8-4.0)
Genesis II	Genesis II	63,915	69 (63-75)	1,359	0.4 (0.3-0.4)	1.6 (1.5-1.7)	2.2 (2.0-2.3)	2.5 (2.4-2.6)	2.9 (2.7-3.0)	3.2 (2.9-3.4)
NexGen	NexGen	60,333	69 (63-75)	1,578	0.3 (0.3-0.4)	1.4 (1.3-1.5)	2.1 (2.0-2.2)	2.9 (2.7-3.0)	3.9 (3.7-4.1)	4.9 (4.6-5.3)
Vanguard Complete Knee	Vanguard Complete Knee	48,103	69 (62-75)	913	0.4 (0.3-0.4)	1.4 (1.3-1.5)	1.9 (1.7-2.0)	2.2 (2.0-2.3)	2.6 (2.4-2.8)	3.2 (2.9-3.6)
PFC / SIGMA	PFC / SIGMA	31,886	70 (63-76)	560	0.3 (0.2-0.3)	1.2 (1.1-1.3)	1.7 (1.5-1.8)	1.9 (1.7-2.0)	2.2 (2.0-2.3)	2.4 (2.2-2.6)
LCS	LCS	17,251	70 (63-76)	627	0.4 (0.3-0.5)	2.3 (2.1-2.5)	3.2 (2.9-3.5)	3.8 (3.5-4.1)	4.3 (4.0-4.7)	4.8 (4.4-5.2)
Triathlon	Triathlon	10,507	70 (64-76)	167	0.4 (0.3-0.6)	1.5 (1.2-1.8)	2.1 (1.8-2.5)	2.4 (2.0-2.8)	2.7 (2.2-3.2)	n.a.
Persona	Persona	5,811	69 (62-74)	25	0.3 (0.1-0.4)	1.0 (0.4-1.6)	2.3 (0.9-3.7)	2.8 (1.1-4.6)	n.a.	n.a.
Attune	Attune	5,546	70 (63-75)	32	0.2 (0.1-0.3)	1.0 (0.6-1.4)	1.4 (0.9-1.9)	1.4 (0.9-1.9)	n.a.	n.a.
AGC V2	AGC V2	4,420*	71 (65-77)	116	0.1 (0.0-0.2)	1.1 (0.8-1.4)	1.5 (1.1-1.9)	1.9 (1.5-2.4)	2.4 (1.9-2.9)	3.2 (2.6-3.8)
balanSys	balanSys	4,087	69 (62-76)	86	0.3 (0.1-0.4)	1.4 (1.0-1.8)	2.2 (1.7-2.7)	2.8 (2.2-3.5)	3.3 (2.5-4.0)	3.7 (2.7-4.7)

¹ Revision of at least the femur or tibia component.
* Denotes prosthesis combinations with no reported use in primary TKAs in 2022.
Please note: n.a. if <50 cases were at risk; TKA: total knee arthroplasty; CI: confidence interval; IQR: interquartile range.

Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure of the prosthesis may have influenced the cumulative revision percentages.

Knee » Survival TKA » Revision per component name » Uncemented primary TKA – major revision

TABLE Cumulative major revision percentages of uncemented primary total knee arthroplasties by prosthesis component combination of patients who underwent a TKA for osteoarthritis in the Netherlands in 2007-2022 (n=14,982)

					Cumulative major revision percentage Kaplan Meier (95% CI)
Femur component	Tibia component	Total primary TKAs (n)	Median (IQR) age (yr)	Major revision¹ arthroplasties (n)	1yr	3yr	5yr	7yr	10yr	14yr
All uncemented TKAs for osteoarthritis		14,982	69 (62-75)	414	0.6 (0.5-0.7)	2.1 (1.9-2.4)	2.7 (2.4-3.0)	3.1 (2.8-3.4)	3.5 (3.2-3.9)	4.0 (3.5-4.5)
LCS	LCS	9,032	69 (63-76)	237	0.6 (0.4-0.7)	2.2 (1.8-2.5)	2.7 (2.3-3.0)	2.8 (2.4-3.2)	3.0 (2.6-3.4)	3.3 (2.8-3.7)
Triathlon	Triathlon	2,293	68 (62-74)	20	0.3 (0.0-0.5)	0.6 (0.2-1.0)	1.1 (0.5-1.7)	1.5 (0.7-2.2)	2.5 (1.1-3.8)	n.a.
ACS	ACS	702	69 (61-75)	18	1.4 (0.5-2.4)	2.7 (1.4-4.1)	3 (1.6-4.4)	3.3 (1.8-4.8)	n.a.	n.a.
Attune	Attune	467	67 (61-73)	3	0.2 (0.0-0.7)	1.4 (0.0-3.1)	n.a.	n.a.	n.a.	n.a.
Duracon	Duracon	296*	69 (61-77)	4	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.4 (0.0-1.1)	0.4 (0.0-1.1)	1.6 (0.0-3.1)	1.6 (0.0-3.1)
Rotaglide	Rotaglide	271*	69 (61-77)	49	0.4 (0.0-1.1)	6.5 (3.5-9.5)	11.3 (7.4-15.2)	15.2 (10.7-19.6)	18.1 (13.2-23)	n.a.
NexGen	NexGen	241	69 (63-77)	13	1.3 (0.0-2.8)	4.0 (1.4-6.6)	5.0 (2.1-7.9)	5.9 (2.5-9.3)	5.9 (2.5-9.3)	n.a.
ACS LD	ACS LD	249*	70 (61-76)	9	1.3 (0.0-2.8)	3.5 (1.1-5.9)	4.1 (1.5-6.7)	n.a.	n.a.	n.a.
Genesis II	Genesis II	234	69 (62-75)	6	0.5 (0.0-1.3)	3.0 (0.6-5.3)	3.0 (0.6-5.3)	3.0 (0.6-5.3)	3.0 (0.6-5.3)	n.a.
Vanguard Complete Knee	Vanguard Complete Knee	168	67 (61-74)	11	1.9 (0.0-4.0)	4.5 (1.2-7.7)	4.5 (1.2-7.7)	5.5 (1.7-9.2)	8.0 (3.0-13.1)	n.a.

Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure of the prosthesis may have influenced the cumulative revision percentages.

Knee » Survival TKA » Revision per component name » Bone cement

TABLE Cumulative revision percentages of the most frequently registered types of bone cement by type of mixing system in primary total knee arthroplasties in the Netherlands in 2007-2022

			Cumulative revision percentage Kaplan Meier (95% CI)
Bone cement	Total primary TKAs (n)	Total RAs (n)	1yr	3yr	5yr	7yr	10yr	14yr
Separately packed	186,441	9,094	0.9 (0.9-1.0)	3.3 (3.2-3.4)	4.3 (4.2-4.4)	5.0 (4.9-5.1)	5.9 (5.7-6.0)	6.9 (6.7-7.1)
Palacos R+G	139,537	6,691	0.9 (0.9-1.0)	3.3 (3.2-3.4)	4.3 (4.2-4.4)	5.0 (4.8-5.1)	5.8 (5.7-6.0)	6.9 (6.6-7.1)
Refobacin Bone Cement R	13,142	680	0.8 (0.6-0.9)	3.0 (2.7-3.3)	4.0 (3.7-4.4)	5.1 (4.7-5.5)	6.6 (6.1-7.1)	8.0 (7.3-8.7)
Palacos MV+G	8,394	382	0.8 (0.6-1.0)	3.1 (2.7-3.4)	4.1 (3.6-4.5)	4.8 (4.4-5.3)	5.3 (4.7-5.8)	n.a.
Simplex ABC EC	5,374	367	1.0 (0.8-1.3)	3.9 (3.4-4.4)	5.2 (4.6-5.8)	6.2 (5.6-6.9)	7.3 (6.5-8.0)	8.7 (7.4-10.0)
Simplex ABC TOBRA	5,165	232	0.8 (0.5-1.0)	2.2 (1.8-2.6)	3.0 (2.5-3.5)	3.6 (3.1-4.1)	4.7 (4.0-5.3)	6.5 (5.2-7.8)
Refobacin Plus Bone Cement	3,163	205	1.1 (0.7-1.4)	4.4 (3.6-5.1)	5.4 (4.6-6.2)	5.9 (5.1-6.8)	6.5 (5.6-7.3)	7.1 (6.1-8.1)
Palacos R	1,753	80	0.6 (0.2-0.9)	2.6 (1.8-3.4)	3.3 (2.4-4.1)	3.9 (3.0-4.8)	4.7 (3.6-5.7)	5.3 (4.1-6.5)
Subiton G	1,550	53	1.4 (0.8-2.1)	4.9 (3.5-6.3)	n.a.	n.a.	n.a.	n.a.
Biomet Plus Bone Cement	1,472	66	1.0 (0.5-1.5)	3.5 (2.5-4.4)	4.4 (3.3-5.5)	4.6 (3.5-5.7)	5.0 (3.7-6.2)	n.a.
Palamed G	1,430	60	0.2 (0.0-0.4)	2.3 (1.5-3.0)	3.1 (2.2-4.1)	3.5 (2.6-4.5)	4.0 (3.0-5.0)	4.7 (3.5-5.9)
Biomet Bone Cement R	884	23	0.8 (0.2-1.4)	3.6 (1.9-5.4)	4.7 (2.4-6.9)	5.6 (2.7-8.5)	5.6 (2.7-8.5)	n.a.
Versabond	647	51	0.6 (0.0-1.2)	5.3 (3.6-7.0)	6.3 (4.4-8.1)	6.8 (4.8-8.7)	7.3 (5.3-9.3)	n.a.
cemSys 1G	636	46	1.4 (0.5-2.3)	3.8 (2.3-5.3)	6.2 (4.3-8.1)	7.2 (5.1-9.3)	n.a.	n.a.
Simplex P	409	22	0 (0-0)	2.8 (1.2-4.4)	3.8 (1.9-5.7)	4.4 (2.3-6.4)	5.3 (3.0-7.5)	6.1 (3.6-8.6)
Simplex HV	382	8	0.8 (0.0-1.7)	2.0 (0.5-3.5)	3.2 (0.4-6.0)	n.a.	n.a.	n.a.
Synicem1G	339	12	0.6 (0.0-1.4)	3.6 (1.6-5.6)	3.6 (1.6-5.6)	n.a.	n.a.	n.a.
Palamed	250	14	0.8 (0.0-1.9)	2.8 (0.8-4.8)	4.0 (1.6-6.4)	4.9 (2.2-7.5)	5.3 (2.5-8.1)	5.8 (2.8-8.8)
Pre-packed in a vacuum mixing system	96,573	3,230	1.0 (1.0-1.1)	3.3 (3.2-3.4)	4.2 (4-4.3)	4.8 (4.6-5.0)	5.6 (5.3-5.8)	6.8 (5.9-7.6)
Refobacin Bone Cement R	43,169	1,453	1.1 (1.0-1.2)	3.2 (3.1-3.4)	4.2 (3.9-4.4)	4.9 (4.6-5.2)	5.6 (5.3-6.0)	n.a.
Palacos R+G	35,186	974	1.1 (1.0-1.2)	3.3 (3.1-3.6)	4.1 (3.9-4.4)	4.7 (4.3-5.1)	n.a.	n.a.
Refobacin Plus Bone Cement	16,356	687	0.7 (0.6-0.9)	3.2 (2.9-3.5)	4.0 (3.7-4.3)	4.5 (4.2-4.9)	5.3 (4.9-5.7)	6.7 (5.5-7.9)
Cemex Genta	1,444*	100	1.0 (0.5-1.6)	4.9 (3.8-6.0)	5.6 (4.4-6.8)	6.2 (5.0-7.5)	7.2 (5.8-8.6)	n.a.

* Denotes types of bone cement with no reported use in primary TKAs in 2022.
Please note: n.a. if <50 cases were at risk; TKA: total knee arthroplasty; RA: revision arthroplasy; CI: confidence interval; IQR: interquartile range.

Only types of bone cement with over 250 procedures have been listed.
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure of the prosthesis may have influenced the cumulative revision percentages.

This website is only accessable on large screens